Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

NCT01887587 is registered in ClinicalTrials.gov with Ehab L Atallah as lead sponsor.

NCT NCT01887587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01887587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
Lead sponsor
Ehab L Atallah
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2013
Completion date
February 29, 2016
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mixed phenotype acute leukemia, relapsed or refractory acute lymphoblastic leukemia, relapsed or refractory lymphoblastic lymphoma